Not long after the pre-clinical DEX cancer vaccine reports were published, the use of TEX was reported as a potent source of immunogenic targets in murine tumor models TS/A, P815, and MC38 [84]—including the ability of TEX from one tumor to cross-prime antigens that led to rejection of the other tumor type (with a different MHC background). The gene discussed is HLA-C; the disease is neoplasm.